---
schema_version: "secwatch.filing_event.v1"
accession: "0001339970-26-000027"
form_type: "8-K"
ticker: "ATYR"
cik: "0001339970"
company_name: "aTYR PHARMA INC"
filed_at: "2026-05-11T20:03:51+00:00"
generated_at: "2026-05-11T22:54:48.499418+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# aTyr Pharma to launch new Phase 3 study of efzofitimod in pulmonary sarcoidosis after FDA feedback

## Summary
- Cash, cash equivalents, and investments totaled $68.3M as of March 31, 2026 (unaudited).
- FDA Type C meeting endorsed FVC as primary endpoint and KSQ-Lung as key secondary in new Phase 3.
- New trial to enroll ~372 patients with restrictive lung disease (FVC ≤80% predicted) on stable corticosteroids.
- Dosing changed to 5.0 mg/kg every 3 weeks (from every 4 weeks) with enhanced safety monitoring.
- Company plans to submit IND for this Phase 3 study in June 2026.

## SEC filing metadata
- accession: 0001339970-26-000027
- form_type: 8-K
- ticker: ATYR
- cik: 0001339970
- company_name: aTYR PHARMA INC
- filed_at: 2026-05-11T20:03:51+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339970/000133997026000027/0001339970-26-000027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339970/000133997026000027/atyr-20260511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001339970-26-000027
- JSON: https://secwatch.observer/filing/0001339970-26-000027.json
- Plain text: https://secwatch.observer/filing/0001339970-26-000027.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.